Understanding why some lung cancer patients don't respond to immunotherapy
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
This study is looking into why some patients with lung cancer and LKB1 gene mutations don’t respond well to immunotherapy, and it hopes to find new ways to boost their immune systems to fight the cancer better.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10861801 on NIH RePORTER |
What this research studies
This research investigates the reasons behind the resistance to immunotherapy in patients with lung adenocarcinoma who have mutations in the LKB1 gene. The team aims to develop personalized treatment strategies by exploring how these mutations affect tumor growth and immune response. They will utilize advanced techniques to analyze the metabolic changes and immune suppression caused by LKB1 loss, with the goal of identifying new therapeutic options that could enhance the effectiveness of existing treatments. Patients with LKB1 mutations may benefit from innovative approaches that reactivate their immune systems against cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have LKB1 mutations.
Not a fit: Patients without LKB1 mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for lung cancer patients with LKB1 mutations, improving their response to immunotherapy.
How similar studies have performed: Previous research has shown promising results in targeting specific genetic mutations in cancer, indicating potential for success in this novel approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Fu, Haian — Emory University
- Study coordinator: Fu, Haian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.